Insider Transactions in Q3 2024 at Soleno Therapeutics Inc (SLNO)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 29
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,870
-2.58%
|
$322,890
$47.5 P/Share
|
|
Aug 29
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,435
-3.05%
|
$255,445
$47.5 P/Share
|
|
Aug 29
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
58,391
-3.69%
|
$2,744,377
$47.5 P/Share
|
|
Aug 29
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,435
-2.33%
|
$255,445
$47.5 P/Share
|
|
Aug 29
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-1.56%
|
$4,700,000
$47.22 P/Share
|
|
Aug 28
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,661
-2.39%
|
$313,067
$47.61 P/Share
|
|
Aug 28
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,270
-2.8%
|
$247,690
$47.61 P/Share
|
|
Aug 28
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
56,613
-3.36%
|
$2,660,811
$47.61 P/Share
|
|
Aug 28
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,270
-2.17%
|
$247,690
$47.61 P/Share
|
|
Aug 28
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
425,000
-6.23%
|
$19,975,000
$47.35 P/Share
|
|
Aug 27
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
500,000
-6.83%
|
$24,000,000
$48.73 P/Share
|
|
Aug 15
2024
|
Dawn Carter Bir |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+50.0%
|
-
|
|
Aug 06
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
69,131
-2.54%
|
$3,041,764
$44.93 P/Share
|
|
Aug 06
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,977
-1.57%
|
$262,988
$44.93 P/Share
|
|
Aug 06
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,134
-1.85%
|
$357,896
$44.93 P/Share
|
|
Aug 06
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,957
-1.99%
|
$262,108
$44.93 P/Share
|
|
Aug 05
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
58,213
-3.0%
|
$2,619,585
$45.81 P/Share
|
|
Aug 05
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,032
-1.9%
|
$226,440
$45.81 P/Share
|
|
Aug 05
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,849
-2.22%
|
$308,205
$45.81 P/Share
|
|
Aug 05
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,017
-2.39%
|
$225,765
$45.81 P/Share
|
|
Jul 17
2024
|
Meredith Manning Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Jul 17
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
850,000
+46.36%
|
-
|
|
Jul 17
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+39.1%
|
-
|
|
Jul 17
2024
|
Patricia C Hirano |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+38.86%
|
-
|
|
Jul 17
2024
|
Kristen Yen |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+44.44%
|
-
|
|
Jul 17
2024
|
Michael F. Huang Sr. VP of Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
|
Jul 01
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
2,170
-4.71%
|
$88,970
$41.43 P/Share
|
|
Jul 01
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
19,256
-6.44%
|
$789,496
$41.43 P/Share
|
|
Jul 01
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
2,170
-2.15%
|
$88,970
$41.43 P/Share
|
|
Jul 01
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
7,190
-5.82%
|
$294,790
$41.43 P/Share
|